Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
cagrisema
CagriSema is Novo Nordisk's 1:1 co-formulation of cagrilintide (long-acting amylin analog) and semaglutide (GLP-1 agonist). In Phase III for obesity and T2D; ~22% weight loss reported in Phase II.
Cagrilintide provides amylin-mediated satiety and slowed gastric emptying; semaglutide provides GLP-1-mediated appetite suppression and insulin release. Complementary mechanisms.
REDEFINE Phase III program completed 2024; Phase II REDEFINE-2 showed ~22% weight loss at 68 weeks (highest dose).
Typical Dose
Varies by vendor (1:1 ratio)
Frequency
Weekly
Route
SubQ
Notes
Total mg reflects summed content of cagrilintide + semaglutide.
Build a protocol with CagriSema, schedule blood work for key biomarkers, and track your results.
Build Protocol with CagriSemaThis platform provides informational tools only, not medical advice. This information is for educational purposes only. Consult a licensed provider.
Disclosed Labs